Literature DB >> 14557527

Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.

Mary F Brunette1, Douglas L Noordsy, Haiyi Xie, Robert E Drake.   

Abstract

OBJECTIVES: Because use of benzodiazepines may exacerbate existing substance use disorders or become abused substances, prescription of benzodiazepines for patients with severe mental illness (schizophrenia or bipolar disorder) and co-occurring substance use disorders (abuse or dependence) is controversial. The authors examined benzodiazepine use and associated psychiatric, substance abuse, and institutional outcomes in a six-year longitudinal study of patients with co-occurring disorders.
METHODS: At baseline and yearly follow-up for six years, 203 patients with co-occurring severe mental illness and substance use disorder were prospectively assessed for medication use, substance use, psychiatric symptoms, use of hospitalization, and quality of life.
RESULTS: Almost one-half of the patients (43 percent) reported taking prescribed benzodiazepines at the time of at least one assessment. Patients taking prescribed benzodiazepines were more likely to have high scores on measures of overall symptoms and affective symptoms (anxiety and depression) and low ratings for general quality of life throughout the study. Benzodiazepine use was unrelated to remission of substance use disorder or hospitalization, but a greater proportion of patients who were prescribed benzodiazepines developed benzodiazepine abuse, compared with those who were not prescribed benzodiazepines (15 percent compared with 6 percent).
CONCLUSIONS: Prescription benzodiazepine use was common among patients with co-occurring severe mental illness and a substance use disorder and was not associated with any of the measured outcomes other than increasing the likelihood of benzodiazepine abuse. Physicians should consider other treatments for anxiety in this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557527     DOI: 10.1176/appi.ps.54.10.1395

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  36 in total

1.  Management of persons with co-occurring severe mental illness and substance use disorder: program implications.

Authors:  Robert E Drake; Kim T Mueser; Mary F Brunette
Journal:  World Psychiatry       Date:  2007-10       Impact factor: 49.548

2.  Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.

Authors:  William V Bobo; Noreen A Reilly-Harrington; Terence A Ketter; Benjamin D Brody; Gustavo Kinrys; David E Kemp; Richard C Shelton; Susan L McElroy; Louisa G Sylvia; James H Kocsis; Melvin G McInnis; Edward S Friedman; Vivek Singh; Mauricio Tohen; Charles L Bowden; Thilo Deckersbach; Joseph R Calabrese; Michael E Thase; Andrew A Nierenberg; Dustin J Rabideau; David A Schoenfeld; Stephen V Faraone; Masoud Kamali
Journal:  J Affect Disord       Date:  2014-03-13       Impact factor: 4.839

3.  Factors associated with benzodiazepine prescribing in community mental health settings.

Authors:  Lauren Jessell; Victoria Stanhope; Jennifer I Manuel; Pedro Mateu-Gelabert
Journal:  J Subst Abuse Treat       Date:  2019-11-22

4.  A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder.

Authors:  Ranran Li; Renrong Wu; Jun Chen; David E Kemp; Ming Ren; Carla Conroy; Philip Chan; Mary Beth Serrano; Stephen J Ganocy; Joseph R Calabrese; Keming Gao
Journal:  Psychopharmacol Bull       Date:  2016-03-01

5.  Association Between Nonmedical Use of Prescription Drugs and Sleep Quality in a Large College Student Sample.

Authors:  Yahya A Alamir; Keith J Zullig; Sijin Wen; Hawley Montgomery-Downs; Alfgeir L Kristjansson; Ranjita Misra; Jianjun Zhang
Journal:  Behav Sleep Med       Date:  2017-12-22       Impact factor: 2.964

6.  Benzodiazepine Maintenance Treatment in Schizophrenia.

Authors:  Simriti K Chaudhry; Lauren Broderick; Julie B Penzner; Jonathan Avery
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-17

7.  Benzodiazepine Dependence among Young Adult Participants in the Club Scene Who Use Drugs.

Authors:  Steven P Kurtz; Mance E Buttram; Hilary L Surratt
Journal:  J Psychoactive Drugs       Date:  2016-12-21

8.  Benzodiazepine dependence among multidrug users in the club scene.

Authors:  Steven P Kurtz; Hilary L Surratt; Maria A Levi-Minzi; Angela Mooss
Journal:  Drug Alcohol Depend       Date:  2011-06-25       Impact factor: 4.492

9.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

10.  Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Authors:  Zev Schuman-Olivier; Bettina B Hoeppner; Roger D Weiss; Jacob Borodovsky; Howard J Shaffer; Mark J Albanese
Journal:  Drug Alcohol Depend       Date:  2013-05-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.